Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma

被引：11
|
作者：
De Dosso, Sara [1 ]
Martin, Vittoria [2 ]
Zanellato, Elena [2 ]
Frattini, Milo [2 ]
Saletti, Piercarlo [1 ]
机构：
[1] Oncol Inst So Switzerland, CH-6500 Bellinzona, Switzerland
[2] Ist Cantonale Patol, Lab Mol Diagnost, Locarno, Switzerland
来源：
TUMORI | 2010年 / 96卷 / 04期
关键词：
anal cancer; cetuximab; EGFR; K-Ras; METASTATIC COLORECTAL-CANCER; SINGLE-AGENT; PHASE-II; IRINOTECAN; CHEMOTHERAPY;
D O I：
10.1177/030089161009600419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
There are no standard chemotherapeutic options for patients with squamous cell anal carcinoma, relapsing and progressing on palliative cisplatin-based regimens. Similarly to other malignant conditions, monoclonal antibodies directed against the epidermal growth factor receptor may represent an attractive therapeutic strategy. Here we describe a patient who, based on molecular profile, benefited from the combination of irinotecan and cetuximab. Free full text available at www.tumorionline.it
引用
收藏
页码：627 / 628
页数：2
相关论文
共 50 条
  • [1] Cetuximab in Refractory Squamous Cell Carcinoma of the Anal Canal
    Rogers J.E.
    Eng C.
    Journal of Gastrointestinal Cancer, 2014, 45 (Suppl 1) : 198 - 200
  • [2] Molecular characterization of squamous cell carcinoma of the anal canal
    Armstrong, Samantha A.
    Malley, Rita
    Wang, Hongkun
    Lenz, Heinz-Josef
    Arguello, David
    El-Deiry, Wafik S.
    Xiu, Joanne
    Gatalica, Zoran
    Hwang, Jimmy J.
    Philip, Philip A.
    Shields, Anthony F.
    Marshall, John L.
    Salem, Mohamed E.
    Weinberg, Benjamin A.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (05) : 2423 - +
  • [3] Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight
    Peddi, Prakash
    Paryani, Bhavna
    Takalkar, Amol
    Bundrick, Paige
    Ponugupati, John
    Nair, Binu
    El-Osta, Hazem
    ONCOTARGETS AND THERAPY, 2016, 9 : 705 - 708
  • [4] Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: Report of a case
    Phan, Lan K.
    Hoff, Paulo M.
    DISEASES OF THE COLON & RECTUM, 2007, 50 (03) : 395 - 398
  • [5] Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
    Hober, Candice
    Jamme, Philippe
    Desmedt, Eve
    Greliak, Anna
    Mortier, Laurent
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [6] Molecular characterization of squamous cell carcinoma of the anal canal (SCCA).
    Weinberg, Benjamin Adam
    Lenz, Heinz-Josef
    Arguello, David
    El-Deiry, Wafik S.
    Xiu, Joanne
    Gatalica, Zoran
    Liu, Zhuqing
    Chen, Sting
    El Ghazaly, Hesham
    Hwang, Jimmy J.
    Philip, Philip Agop
    Shields, Anthony Frank
    Marshall, John
    Salem, Mohamed E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [7] Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal
    Rogers, Jane E.
    Silva, Ninoska N.
    Eng, Cathy
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (05) : E82 - E85
  • [8] Relapsed refractory metastatic squamous cell cancer of anal canal in a patient with retroviral infection responding to cetuximab
    Lerner, Jaren
    Michel, Miguel
    Dasanu, Constantin A.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (04) : 1025 - 1028
  • [9] Squamous cell carcinoma of the skin - Cetuximab Response
    Mansinho, A.
    Sousa, R.
    Costa, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 90 - 90
  • [10] Complete Clinical Response to Cetuximab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
    Miller, Kristen
    Sherman, William
    Ratner, Desiree
    DERMATOLOGIC SURGERY, 2010, 36 (12) : 2069 - 2074
12345